CN100352448C - 用于预防药物耐受性的用途和组合物 - Google Patents

用于预防药物耐受性的用途和组合物 Download PDF

Info

Publication number: CN100352448C
Authority: CN; China
Prior art keywords: purposes; administration; bronchodilator; molecular weight; low molecular
Prior art date: 1998-10-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CNB2004100629128A

Other languages

English (en)

Chinese (zh)

Other versions

CN1572303A (zh

Inventor

T·阿迈德

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Tahir Ahmed

Teva Branded Pharmaceutical Products R&D Inc

Original Assignee

Ivax Research Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-30

Filing date

1999-10-13

Publication date

2007-12-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26803748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100352448(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-10-13 Application filed by Ivax Research Inc filed Critical Ivax Research Inc

2005-02-02 Publication of CN1572303A publication Critical patent/CN1572303A/zh

2007-12-05 Application granted granted Critical

2007-12-05 Publication of CN100352448C publication Critical patent/CN100352448C/zh

2019-10-13 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 52
239000003814 drug Substances 0.000 title claims description 40
230000002265 prevention Effects 0.000 title claims description 11
229940079593 drug Drugs 0.000 title claims description 6
238000000034 method Methods 0.000 title abstract description 54
238000002483 medication Methods 0.000 title description 2
229940124630 bronchodilator Drugs 0.000 claims abstract description 66
239000000048 adrenergic agonist Substances 0.000 claims abstract description 27
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 64
229960002897 heparin Drugs 0.000 claims description 61
229920000669 heparin Polymers 0.000 claims description 61
208000006673 asthma Diseases 0.000 claims description 57
238000011282 treatment Methods 0.000 claims description 48
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 41
238000002360 preparation method Methods 0.000 claims description 34
229940127215 low-molecular weight heparin Drugs 0.000 claims description 27
210000000621 bronchi Anatomy 0.000 claims description 25
150000004676 glycans Chemical class 0.000 claims description 25
239000003055 low molecular weight heparin Substances 0.000 claims description 25
229920001282 polysaccharide Polymers 0.000 claims description 23
239000005017 polysaccharide Substances 0.000 claims description 23
230000007170 pathology Effects 0.000 claims description 22
241000124008 Mammalia Species 0.000 claims description 17
239000000443 aerosol Substances 0.000 claims description 15
239000000843 powder Substances 0.000 claims description 14
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 9
230000000241 respiratory effect Effects 0.000 claims description 9
150000001720 carbohydrates Chemical class 0.000 claims description 7
229960002052 salbutamol Drugs 0.000 claims description 7
-1 bitolferol Chemical compound 0.000 claims description 6
239000007921 spray Substances 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 4
229960002848 formoterol Drugs 0.000 claims description 4
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 4
150000003538 tetroses Chemical class 0.000 claims description 4
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 3
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 3
HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 claims description 3
VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims description 3
MKFFGUZYVNDHIH-UHFFFAOYSA-N [2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]-propan-2-ylazanium;sulfate Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC(O)=CC(O)=C1.CC(C)NCC(O)C1=CC(O)=CC(O)=C1 MKFFGUZYVNDHIH-UHFFFAOYSA-N 0.000 claims description 3
229960003060 bambuterol Drugs 0.000 claims description 3
ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 claims description 3
229940039009 isoproterenol Drugs 0.000 claims description 3
229960005414 pirbuterol Drugs 0.000 claims description 3
229960000195 terbutaline Drugs 0.000 claims description 3
239000006196 drop Substances 0.000 claims description 2
229940112141 dry powder inhaler Drugs 0.000 claims description 2
238000007918 intramuscular administration Methods 0.000 claims description 2
238000001990 intravenous administration Methods 0.000 claims description 2
210000000664 rectum Anatomy 0.000 claims description 2
230000000699 topical effect Effects 0.000 claims description 2
230000002429 anti-coagulating effect Effects 0.000 claims 2
239000012120 mounting media Substances 0.000 claims 2
239000003889 eye drop Substances 0.000 claims 1
229940012356 eye drops Drugs 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 abstract description 7
239000000168 bronchodilator agent Substances 0.000 abstract description 3
239000012636 effector Substances 0.000 description 50
229960002931 methacholine chloride Drugs 0.000 description 21
JHPHVAVFUYTVCL-UHFFFAOYSA-M methacholine chloride Chemical compound [Cl-].C[N+](C)(C)CC(C)OC(C)=O JHPHVAVFUYTVCL-UHFFFAOYSA-M 0.000 description 18
230000001681 protective effect Effects 0.000 description 15
230000037396 body weight Effects 0.000 description 14
239000000556 agonist Substances 0.000 description 12
230000000694 effects Effects 0.000 description 12
210000002345 respiratory system Anatomy 0.000 description 11
230000008859 change Effects 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
229940068196 placebo Drugs 0.000 description 10
239000000902 placebo Substances 0.000 description 10
239000000243 solution Substances 0.000 description 10
239000000463 material Substances 0.000 description 9
230000008569 process Effects 0.000 description 9
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
238000011160 research Methods 0.000 description 8
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 8
206010006482 Bronchospasm Diseases 0.000 description 7
206010061218 Inflammation Diseases 0.000 description 7
230000004054 inflammatory process Effects 0.000 description 7
230000007246 mechanism Effects 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
229920002683 Glycosaminoglycan Polymers 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
239000007788 liquid Substances 0.000 description 6
230000029058 respiratory gaseous exchange Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000002585 base Substances 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
229960000265 cromoglicic acid Drugs 0.000 description 5
238000000586 desensitisation Methods 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 5
230000003203 everyday effect Effects 0.000 description 5
230000000670 limiting effect Effects 0.000 description 5
230000033001 locomotion Effects 0.000 description 5
230000026731 phosphorylation Effects 0.000 description 5
238000006366 phosphorylation reaction Methods 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
208000009079 Bronchial Spasm Diseases 0.000 description 4
208000014181 Bronchial disease Diseases 0.000 description 4
108090000190 Thrombin Proteins 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000003246 corticosteroid Substances 0.000 description 4
239000000890 drug combination Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
229960001340 histamine Drugs 0.000 description 4
210000003630 histaminocyte Anatomy 0.000 description 4
229920001542 oligosaccharide Polymers 0.000 description 4
150000002482 oligosaccharides Chemical class 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
239000003826 tablet Substances 0.000 description 4
229960000278 theophylline Drugs 0.000 description 4
229960004072 thrombin Drugs 0.000 description 4
206010002198 Anaphylactic reaction Diseases 0.000 description 3
102000004411 Antithrombin III Human genes 0.000 description 3
108090000935 Antithrombin III Proteins 0.000 description 3
102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
108010022901 Heparin Lyase Proteins 0.000 description 3
206010027336 Menstruation delayed Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
208000018569 Respiratory Tract disease Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
230000036783 anaphylactic response Effects 0.000 description 3
208000003455 anaphylaxis Diseases 0.000 description 3
230000001078 anti-cholinergic effect Effects 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
229940127219 anticoagulant drug Drugs 0.000 description 3
229960005348 antithrombin iii Drugs 0.000 description 3
238000007068 beta-elimination reaction Methods 0.000 description 3
230000007885 bronchoconstriction Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
210000000038 chest Anatomy 0.000 description 3
230000018044 dehydration Effects 0.000 description 3
238000006297 dehydration reaction Methods 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
229960000610 enoxaparin Drugs 0.000 description 3
238000006911 enzymatic reaction Methods 0.000 description 3
239000002634 heparin fragment Substances 0.000 description 3
229960001361 ipratropium bromide Drugs 0.000 description 3
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 3
239000007937 lozenge Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
230000035479 physiological effects, processes and functions Effects 0.000 description 3
239000003380 propellant Substances 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
238000005507 spraying Methods 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
210000000115 thoracic cavity Anatomy 0.000 description 3
241000283690 Bos taurus Species 0.000 description 2
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
102000009123 Fibrin Human genes 0.000 description 2
108010073385 Fibrin Proteins 0.000 description 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
229920001503 Glucan Polymers 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000001785 acacia senegal l. willd gum Substances 0.000 description 2
102000030621 adenylate cyclase Human genes 0.000 description 2
108060000200 adenylate cyclase Proteins 0.000 description 2
239000003513 alkali Substances 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
229950003499 fibrin Drugs 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 2
206010025482 malaise Diseases 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000007932 molded tablet Substances 0.000 description 2
150000002826 nitrites Chemical class 0.000 description 2
230000000474 nursing effect Effects 0.000 description 2
239000006072 paste Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
150000004804 polysaccharides Polymers 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000009613 pulmonary function test Methods 0.000 description 2
230000010076 replication Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
230000016160 smooth muscle contraction Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000032258 transport Effects 0.000 description 2
210000001215 vagina Anatomy 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
229920001287 Chondroitin sulfate Polymers 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
RGHNJXZEOKUKBD-MBMOQRBOSA-N D-mannonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O RGHNJXZEOKUKBD-MBMOQRBOSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
229920000045 Dermatan sulfate Polymers 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000277306 Esocidae Species 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010028665 Myxoedema Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
241001136275 Sphingobacterium Species 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
206010046306 Upper respiratory tract infection Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000009471 action Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000001919 adrenal effect Effects 0.000 description 1
239000000464 adrenergic agent Substances 0.000 description 1
210000001552 airway epithelial cell Anatomy 0.000 description 1
210000005091 airway smooth muscle Anatomy 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
229960003556 aminophylline Drugs 0.000 description 1
FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
102000016959 beta-3 Adrenergic Receptors Human genes 0.000 description 1
108010014502 beta-3 Adrenergic Receptors Proteins 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
201000009267 bronchiectasis Diseases 0.000 description 1
210000003123 bronchiole Anatomy 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007894 caplet Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229940059329 chondroitin sulfate Drugs 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
239000004567 concrete Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
238000005336 cracking Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
229940051593 dermatan sulfate Drugs 0.000 description 1
238000013461 design Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000000539 dimer Substances 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000000222 eosinocyte Anatomy 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000007897 gelcap Substances 0.000 description 1
210000000224 granular leucocyte Anatomy 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000007373 indentation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003434 inspiratory effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
AEMOLEFTQBMNLQ-CLQWQSTFSA-N l-iduronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@@H]1O AEMOLEFTQBMNLQ-CLQWQSTFSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
150000002730 mercury Chemical class 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
208000003786 myxedema Diseases 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 description 1
229960000797 oxitropium Drugs 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000011505 plaster Substances 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
229940063566 proventil Drugs 0.000 description 1
239000002994 raw material Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
210000001533 respiratory mucosa Anatomy 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
229960004017 salmeterol Drugs 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229940090585 serevent Drugs 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003506 spasmogen Substances 0.000 description 1
235000013599 spices Nutrition 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000011272 standard treatment Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
210000002820 sympathetic nervous system Anatomy 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
229960000257 tiotropium bromide Drugs 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
229940120293 vaginal suppository Drugs 0.000 description 1
239000006216 vaginal suppository Substances 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
239000002550 vasoactive agent Substances 0.000 description 1
229940070384 ventolin Drugs 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Investigating Or Analysing Biological Materials (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CNB2004100629128A 1998-10-30 1999-10-13 用于预防药物耐受性的用途和组合物 Expired - Fee Related CN100352448C (zh)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US10650798P	1998-10-30	1998-10-30
US60/106,507		1998-10-30
US09/362,540		1999-07-28
US09/362,540 US6235725B1 (en)	1998-10-30	1999-07-28	Methods and compositions for the prevention of tolerance to medications

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CN99813923A Division CN1329496A (zh)	1998-10-30	1999-10-13	用于预防药物耐受性的方法和组合物

Publications (2)

Publication Number	Publication Date
CN1572303A CN1572303A (zh)	2005-02-02
CN100352448C true CN100352448C (zh)	2007-12-05

Family

ID=26803748

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CN99813923A Pending CN1329496A (zh)	1998-10-30	1999-10-13	用于预防药物耐受性的方法和组合物
CNB2004100629128A Expired - Fee Related CN100352448C (zh)	1998-10-30	1999-10-13	用于预防药物耐受性的用途和组合物

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CN99813923A Pending CN1329496A (zh)	1998-10-30	1999-10-13	用于预防药物耐受性的方法和组合物

Country Status (25)

Country	Link
US (1)	US6235725B1 (fr)
EP (1)	EP1124563B1 (fr)
JP (1)	JP4585121B2 (fr)
CN (2)	CN1329496A (fr)
AR (2)	AR023911A1 (fr)
AT (1)	ATE277621T1 (fr)
AU (1)	AU760119B2 (fr)
BR (1)	BR9915818A (fr)
CA (1)	CA2348926C (fr)
CO (1)	CO5160320A1 (fr)
CY (1)	CY1107493T1 (fr)
CZ (1)	CZ297914B6 (fr)
DE (1)	DE69920734T2 (fr)
ES (1)	ES2228173T3 (fr)
HK (1)	HK1041596A1 (fr)
HU (1)	HUP0302492A3 (fr)
IL (2)	IL142865A0 (fr)
IS (1)	IS2321B (fr)
NO (1)	NO333194B1 (fr)
NZ (1)	NZ511399A (fr)
PL (1)	PL195592B1 (fr)
PT (1)	PT1124563E (fr)
SK (1)	SK285150B6 (fr)
TW (1)	TW565451B (fr)
WO (1)	WO2000025723A2 (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9902689D0 (en) *	1999-02-08	1999-03-31	Novartis Ag	Organic compounds
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
PL200063B1 (pl) *	2000-10-12	2008-12-31	Boehringer Ingelheim Pharma	Nowe proszki do inhalacji zawierające tiotropium
US6667344B2 (en) *	2001-04-17	2003-12-23	Dey, L.P.	Bronchodilating compositions and methods
US20030055026A1 (en) *	2001-04-17	2003-03-20	Dey L.P.	Formoterol/steroid bronchodilating compositions and methods of use thereof
US20030070679A1 (en) *	2001-06-01	2003-04-17	Boehringer Ingelheim Pharma Kg	Capsules containing inhalable tiotropium
US6702997B2 (en)	2001-10-26	2004-03-09	Dey, L.P.	Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030203930A1 (en) *	2001-10-26	2003-10-30	Imtiaz Chaudry	Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
JP2003221335A (ja)	2001-10-26	2003-08-05	Dey Lp	慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US20030140920A1 (en) *	2001-10-26	2003-07-31	Dey L.P.	Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
US20030191151A1 (en) *	2001-10-26	2003-10-09	Imtiaz Chaudry	Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
WO2003068254A1 (fr) *	2002-02-18	2003-08-21	University Of Southampton	Polytherapie a base de glycosaminoglycane-dnase
ES2565028T3 (es) *	2002-02-18	2016-03-30	Ockham Biotech Limited	Terapia de combinación para trastornos respiratorios
ATE410147T1 (de) *	2002-02-18	2008-10-15	Univ Southampton	Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd
EP1494732B1 (fr)	2002-03-20	2008-01-30	MannKind Corporation	Appareil d'inhalation
JP2006501815A (ja) *	2002-04-25	2006-01-19	モメンタファーマシューティカルズインコーポレイテッド	粘膜送達のための方法および製品
US20040023935A1 (en) *	2002-08-02	2004-02-05	Dey, L.P.	Inhalation compositions, methods of use thereof, and process for preparation of same
RU2327450C2 (ru) *	2002-08-29	2008-06-27	Сипла Лимитед	Фармацевтические продукты и композиции, содержащие специфические антихолинергические средства, агонисты бета-2 и кортикостероиды
US7763280B2 (en) *	2002-11-28	2010-07-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Tiotropium containing powder formulation for inhalation
US20040109826A1 (en) *	2002-12-06	2004-06-10	Dey, L.P.	Stabilized albuterol compositions and method of preparation thereof
JP4851185B2 (ja)	2003-05-16	2012-01-11	ジェレックスインターナショナル株式会社	アレルギー症状抑制剤及び空気濾過フィルター
TWI359675B (en) *	2003-07-10	2012-03-11	Dey L P	Bronchodilating β-agonist compositions
US20050043343A1 (en) *	2003-07-28	2005-02-24	Boehringer Ingelheim International Gmbh	Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor
DK1786784T3 (da)	2004-08-20	2011-02-14	Mannkind Corp	Katalyse af diketopiperazinsyntese
CN104436170B (zh)	2004-08-23	2018-02-23	曼金德公司	用于药物输送的二酮哌嗪盐
AU2006290227B2 (en)	2005-09-14	2012-08-02	Mannkind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
KR20080096809A (ko)	2006-02-22	2008-11-03	맨카인드 코포레이션	디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
SG10201507036TA (en)	2008-06-13	2015-10-29	Mannkind Corp	A dry powder inhaler and system for drug delivery
EP2609954B1 (fr)	2008-06-20	2021-12-29	MannKind Corporation	Appareil interactif pour l'établissement en temps réel d'un profil des efforts d'inhalation
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
MX2011009512A (es)	2009-03-11	2011-11-29	Mannkind Corp	Aparato, sistema y metodo para medir la resistencia de un inhalador.
MY157166A (en)	2009-06-12	2016-05-13	Mankind Corp	Diketopiperazine microparticles with defined specific surface areas
CA2778698A1 (fr)	2009-11-03	2011-05-12	Mannkind Corporation	Appareil et methode de simulation d'efforts d'inhalation
US20130090371A1 (en) *	2010-04-20	2013-04-11	President And Fellows Of Harvard College	Methods and compositions for inhibition of beta2-adrenergic receptor degradation
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
EP2694402B1 (fr)	2011-04-01	2017-03-22	MannKind Corporation	Emballage coque pour cartouches pharmaceutiques
WO2012174472A1 (fr)	2011-06-17	2012-12-20	Mannkind Corporation	Microparticules de dicétopipérazine de capacité élevée
HK1200318A1 (en)	2011-10-24	2015-08-07	曼金德公司	Methods and compositions for treating pain
EP2872205B1 (fr)	2012-07-12	2017-02-08	MannKind Corporation	Systèmes de libération de médicament en poudre sèche
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
WO2014144895A1 (fr)	2013-03-15	2014-09-18	Mannkind Corporation	Compositions de dicétopipérazine microcristallines et procédés
KR102465025B1 (ko)	2013-07-18	2022-11-09	맨카인드 코포레이션	열-안정성 건조 분말 약제학적 조성물 및 방법
EP3030294B1 (fr)	2013-08-05	2020-10-07	MannKind Corporation	Appareil d'insufflation
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
CN104069497A (zh) *	2014-06-27	2014-10-01	东莞市凯法生物医药有限公司	一种降低药物耐受性的组合物、方法及其应用
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
US20190070244A1 (en) *	2017-06-30	2019-03-07	The New Zealand Institute For Plant And Food Research Limited	Boysenberry compositions and methods of preparation and use thereof
WO2019031972A1 (fr)	2017-08-08	2019-02-14	Shaw Odette M	Composition à base de mûre de boysen, de pomme et de cassis et ses procédés de préparation et d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5674860A (en) *	1991-12-18	1997-10-07	Astra Aktiebolag	Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders
US5690910A (en) *	1995-08-18	1997-11-25	Baker Norton Pharmaceuticals, Inc.	Method for treating asthma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1195497B (it)	1983-03-08	1988-10-19	Opocrin Spa	Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4906476A (en)	1988-12-14	1990-03-06	Liposome Technology, Inc.	Novel liposome composition for sustained release of steroidal drugs in lungs
US5380716A (en)	1988-12-15	1995-01-10	Glycomed, Inc.	Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5032679A (en)	1988-12-15	1991-07-16	Glycomed, Inc.	Heparin fragments as inhibitors of smooth muscle cell proliferation
US5192548A (en)	1990-04-30	1993-03-09	Riker Laboratoires, Inc.	Device
SE9302777D0 (sv)	1993-08-27	1993-08-27	Astra Ab	Process for conditioning substances
US5874063A (en)	1991-04-11	1999-02-23	Astra Aktiebolag	Pharmaceutical formulation
US5714376A (en)	1991-10-23	1998-02-03	Massachusetts Institute Of Technology	Heparinase gene from flavobacterium heparinum
ATE128350T1 (de)	1991-12-12	1995-10-15	Glaxo Group Ltd	Pharmazeutische aerosolformulierung.
US5736124A (en)	1991-12-12	1998-04-07	Glaxo Group Limited	Aerosol formulations containing P134a and particulate medicament

1999
- 1999-07-28 US US09/362,540 patent/US6235725B1/en not_active Expired - Lifetime
- 1999-10-13 EP EP99971300A patent/EP1124563B1/fr not_active Expired - Lifetime
- 1999-10-13 AT AT99971300T patent/ATE277621T1/de active
- 1999-10-13 JP JP2000579168A patent/JP4585121B2/ja not_active Expired - Fee Related
- 1999-10-13 PL PL99364727A patent/PL195592B1/pl unknown
- 1999-10-13 DE DE69920734T patent/DE69920734T2/de not_active Expired - Lifetime
- 1999-10-13 HK HK02103273.0A patent/HK1041596A1/zh unknown
- 1999-10-13 HU HU0302492A patent/HUP0302492A3/hu not_active Application Discontinuation
- 1999-10-13 CN CN99813923A patent/CN1329496A/zh active Pending
- 1999-10-13 BR BR9915818-3A patent/BR9915818A/pt not_active Application Discontinuation
- 1999-10-13 PT PT99971300T patent/PT1124563E/pt unknown
- 1999-10-13 ES ES99971300T patent/ES2228173T3/es not_active Expired - Lifetime
- 1999-10-13 SK SK590-2001A patent/SK285150B6/sk not_active IP Right Cessation
- 1999-10-13 AU AU12051/00A patent/AU760119B2/en not_active Ceased
- 1999-10-13 CN CNB2004100629128A patent/CN100352448C/zh not_active Expired - Fee Related
- 1999-10-13 CZ CZ20011518A patent/CZ297914B6/cs not_active IP Right Cessation
- 1999-10-13 CA CA2348926A patent/CA2348926C/fr not_active Expired - Fee Related
- 1999-10-13 WO PCT/US1999/024034 patent/WO2000025723A2/fr not_active Ceased
- 1999-10-13 NZ NZ511399A patent/NZ511399A/en not_active IP Right Cessation
- 1999-10-13 IL IL14286599A patent/IL142865A0/xx active IP Right Grant
- 1999-10-28 AR ARP990105443A patent/AR023911A1/es not_active Application Discontinuation
- 1999-10-29 CO CO99068642A patent/CO5160320A1/es unknown
- 1999-11-09 TW TW088118719A patent/TW565451B/zh not_active IP Right Cessation
2001
- 2001-04-27 NO NO20012097A patent/NO333194B1/no not_active IP Right Cessation
- 2001-04-27 IS IS5928A patent/IS2321B/is unknown
- 2001-04-30 IL IL142865A patent/IL142865A/en not_active IP Right Cessation
2004
- 2004-12-06 CY CY20041101437T patent/CY1107493T1/el unknown
2011
- 2011-09-07 AR ARP110103258A patent/AR082913A2/es not_active Application Discontinuation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5674860A (en) *	1991-12-18	1997-10-07	Astra Aktiebolag	Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders
US5690910A (en) *	1995-08-18	1997-11-25	Baker Norton Pharmaceuticals, Inc.	Method for treating asthma

Also Published As

Publication number	Publication date
PL195592B1 (pl)	2007-10-31
CA2348926A1 (fr)	2000-05-11
CZ297914B6 (cs)	2007-04-25
TW565451B (en)	2003-12-11
AU1205100A (en)	2000-05-22
ES2228173T3 (es)	2005-04-01
IL142865A (en)	2006-07-05
WO2000025723A2 (fr)	2000-05-11
IS5928A (is)	2001-04-27
EP1124563B1 (fr)	2004-09-29
HUP0302492A2 (hu)	2003-11-28
SK285150B6 (sk)	2006-07-07
CZ20011518A3 (cs)	2002-04-17
JP2002535245A (ja)	2002-10-22
HUP0302492A3 (en)	2005-05-30
NO20012097L (no)	2001-06-15
EP1124563A4 (fr)	2002-01-02
US6235725B1 (en)	2001-05-22
PL364727A1 (en)	2004-12-13
IS2321B (is)	2007-12-15
AR023911A1 (es)	2002-09-04
WO2000025723A3 (fr)	2000-07-27
EP1124563A2 (fr)	2001-08-22
HK1041596A1 (zh)	2002-07-12
CY1107493T1 (el)	2013-03-13
DE69920734T2 (de)	2005-10-06
BR9915818A (pt)	2002-06-18
JP4585121B2 (ja)	2010-11-24
CO5160320A1 (es)	2002-05-30
NZ511399A (en)	2004-09-24
AR082913A2 (es)	2013-01-16
AU760119B2 (en)	2003-05-08
CN1329496A (zh)	2002-01-02
DE69920734D1 (de)	2004-11-04
NO333194B1 (no)	2013-04-02
SK5902001A3 (en)	2002-07-02
IL142865A0 (en)	2002-03-10
CA2348926C (fr)	2011-08-23
PT1124563E (pt)	2005-01-31
NO20012097D0 (no)	2001-04-27
ATE277621T1 (de)	2004-10-15
CN1572303A (zh)	2005-02-02

Legal Events

Date	Code	Title	Description
2005-02-02	C06	Publication
2005-02-02	PB01	Publication
2005-04-06	C10	Entry into substantive examination
2005-04-06	SE01	Entry into force of request for substantive examination
2005-05-27	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1069531 Country of ref document: HK
2007-12-05	C14	Grant of patent or utility model
2007-12-05	GR01	Patent grant
2011-05-27	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1069531 Country of ref document: HK
2011-08-31	ASS	Succession or assignment of patent right	Owner name: TEVA BRANDED PHARMACEUTICAL PRODUCTS R + D INC. Free format text: FORMER OWNER: TEVA GLOBAL RESPIRATORY RESEARCH LLC Effective date: 20110726 Owner name: AHMED TAHIR Free format text: FORMER OWNER: TEVA BRANDED PHARMACEUTICAL PRODUCTS R + D INC. Effective date: 20110726
2011-08-31	C41	Transfer of patent application or patent right or utility model
2011-08-31	C56	Change in the name or address of the patentee	Owner name: TEVA GLOBAL RESPIRATORY RESEARCH LLC Free format text: FORMER NAME: IVAX RESEARCH INC. Owner name: IVAX RESEARCH INC. Free format text: FORMER NAME: IVAX RES INC.
2011-08-31	COR	Change of bibliographic data	Free format text: CORRECT: ADDRESS; FROM: FLORIDA, THE USA TO: PENNSYLVANIA, THE USA Free format text: CORRECT: ADDRESS; FROM: PENNSYLVANIA, THE USA TO: FLORIDA, THE USA
2011-08-31	CP01	Change in the name or title of a patent holder	Address after: American Florida Patentee after: TEVA global Respiratory Research Ltd. Address before: American Florida Patentee before: IVAX Research LLC Address after: American Florida Patentee after: IVAX Research LLC Address before: American Florida Patentee before: IVAX RESEARCH, Inc.
2011-08-31	TR01	Transfer of patent right	Effective date of registration: 20110726 Address after: American Florida Patentee after: Tahir Ahmed Address before: American Pennsylvania Patentee before: TEVA high quality pharmaceutical products R & D Co. Effective date of registration: 20110726 Address after: American Pennsylvania Patentee after: TEVA high quality pharmaceutical products R & D Co. Address before: American Florida Patentee before: TEVA global Respiratory Research Ltd.
2018-10-09	CF01	Termination of patent right due to non-payment of annual fee
2018-10-09	CF01	Termination of patent right due to non-payment of annual fee	Granted publication date: 20071205 Termination date: 20171013

Publication	Publication Date	Title
CN1572303A (zh)	2005-02-02	用于预防药物耐受性的方法和组合物
KR100551773B1 (ko)	2006-02-13	후기 알러지 반응 및 염증 질환 치료방법 및 조성물
EP2608847B1 (fr)	2018-03-21	Théobromine combinée à un expectorant ou à un mucolytique et son utilisation en thérapie
JPH06329541A (ja)	1994-11-29	糖尿病性腎症治療用スロデキサイド含有医薬
CN1449288A (zh)	2003-10-15	沙美特罗和丙酸氟地松的药物制剂
WALLER et al.	1982	The effect of probenecid on nafcillin disposition
Hanson	2018	Cough Mixtures–an overview
JP2005510453A (ja)	2005-04-21	高硫酸化二糖類及び炎症治療のためのそれらの使用方法
WO1994005273A1 (fr)	1994-03-17	Compositions gastro-intestinales contenant du dimethylsulfone et du dimethylsulfoxyde
US6579858B1 (en)	2003-06-17	Use of low-molecular-weight heparins for the prevention and treatment of cerebral edemas
EP1773354A2 (fr)	2007-04-18	Compositions de vitamine b12
EP1462148A2 (fr)	2004-09-29	Procédés et compositions pour prévenir la tolérance à des bronchodilateurs
US20070178141A1 (en)	2007-08-02	Vitamin B12 compositions
HK1069137A (en)	2005-05-13	Methods and compositions for the prevention of tolerance to bronchodilators
ZA200103375B (en)	2003-02-06	Methods and compositions for the prevention of tolerance to medications.
HK1069531A (en)	2005-05-27	Methods and compositions for the prevention of tolerance to medications
WO2007030108A1 (fr)	2007-03-15	Compositions de vitamine b12
Turner	1994	Drugs Handbook 1994–95
Nelemans	1989	Antiallergic and antitussive drugs
Brand et al.	1988	The effect of chlorpheniramine maleate on pulmonary function in children with allergic rhinitis with and without asthma
Tattersfield et al.	1987	Drugs Affecting Cough and Sputum
Kirchner	1998	Metformin and troglitazone for type 2 diabetes mellitus.
JPH04305529A (ja)	1992-10-28	経鼻投与製剤
WO1996013270A1 (fr)	1996-05-09	Heparine, preparations d'heparine et leurs techniques d'utilisation